BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: ATP-binding cassette sub-family G WHITE member 1 (ABCG1)

Cardiovascular disease INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting ABCG1 could help treat atherosclerosis. In blood from patients undergoing cardiac catheterization, high levels of ABCG1 in Treg cells correlated with low Treg numbers....
BioCentury | Sep 10, 2015
Distillery Therapeutics

Therapeutics: ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR; BCRP1)

...suggest combining an ABCG2 inhibitor with topotecan could help treat pediatric brain cancer. Levels of ABCG2...
...cancers or normal mice, respectively. In a xenograft mouse model of pediatric brain cancer, an ABCG2...
...topotecan is marketed to treat cervical, lung and ovarian cancers. TARGET/MARKER/PATHWAY: ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR ; BCRP1...
BioCentury | Mar 26, 2015
Distillery Therapeutics

Therapeutics: ATP-binding cassette sub-family G WHITE member 1 (ABCG1)

Cancer INDICATION: Cancer In vitro and mouse studies suggest ABCG1 inhibition could help treat cancer. In co-cultures of mouse tumor-associated macrophages and human cancer cell lines, ABCG1 deficiency in macrophages biased them toward an M1...
BioCentury | Jun 17, 2013
Company News

Dana Farber Cancer Institute, LLS cancer news

The cancer organizations partnered to establish the Blood Cancer Research Partnership (BCRP) network of community oncology sites to participate in Phase I and Phase II testing of blood cancer therapies. The goal of the three-year...
BioCentury | Apr 25, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease ATP-binding cassette sub-family G member 4 (ABCG4); lyn kinase (LYN); thrombopoietin receptor (CD110; Mpl) Cell culture and mouse studies suggest activating LYN...
BioCentury | Mar 28, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...small molecule structural correctors of ABCG2 that could help treat gout. The Q141K mutation in ABCG2...
...gout. SAR studies identified a small molecule that corrected the folding of the Q141K mutant ABCG2...
BioCentury | Oct 22, 2012
Company News

Cyprotex, Sigma-Aldrich sales and marketing update

Sigma Aldrich's Sigma Life Science business granted Cyprotex a non-exclusive license to offer Sigma's transporter knockout cell lines for ADMET screening and safety studies. The assays were developed using CompoZr Zinc Finger Nuclease (ZFN) technology....
BioCentury | Oct 25, 2010
Company News

Charles River, Transposagen Biopharmaceuticals Inc. sales and marketing update

...and a second line with a mutation in the ATP-binding cassette sub-family G WHITE member 2 ( ABCG2 ; MXR ; BCRP1...
BioCentury | Sep 9, 2010
Distillery Techniques

Technology: Drug delivery

...barrier (BBB) drug delivery with ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR; BCRP1) inhibitors Rodent studies suggest that inhibiting BCRP1...
...BCRP1) inhibitors Rodent studies suggest that inhibiting BCRP1 could improve drug delivery through the BBB. BCRP1...
...BCRP1 inhibitor 17b-estradiol reduced Bcrp1-mediated transport compared with that in controls. In mice, 17b-estradiol decreased Bcrp1-mediated...
BioCentury | Jun 17, 2010
Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes ATP-binding cassette sub-family G WHITE member 1 (ABCG1); peroxisome proliferation-activated receptor-g (PPARG; PPARg) In vitro and mouse studies suggest that increasing levels of...
Items per page:
1 - 10 of 20